Marker Ki-67 is a potential biomarker for the diagnosis and prognosis of prostate cancer based on two cohorts

Figure 3 Analysis of the associations between marker Ki-67 expression and clinicopathological characteristics from 271 cases. A-D: The associations between marker Ki-67 (MKI67) expression and clinicopathological characteristics including prostate-specific antigen, Gleason Score, T Stage and N Stage were analyzed through Wilcoxon rank sum test; E: The association between MKI67 expression and progress-free interval (PFI) of prostate cancer (PCa) was analyzed by Kaplan-Meier method. The low- and high expression of MKI67 groups were divided by the median value of MKI67 expression; F: The moderate efficacy of MKI67 expression to predict the 1-, 2-, and 3-year PFI of PCa was proved through time- receiver operating characteristic curve. PSA: Prostate-specific antigen; TPR: True positive rate; HR: Hazard ratio; AUC: Area under the curve.